Lupin receives tentative approval for Empagliflozin and Metformin Hydrochloride ER Tablets

Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received tentative approval for its Empagliflozin and Metformin Hydrochloride ExtendedRelease (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 rng/1000 mg, from the United States Food and Drug Administration, to market a generic equivalent of Synjardy6 XR Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. The product will be manufactured at Lupin's Nagpur facility in India.

Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empaglifiozin and metformin hydrochloride is appropriate.

Empagliflozin and Metformin Hydrochloride ER Tablets (RLD: SynjardytXR) had estimated annual sales of USD 357 million in the U.S. (IQVIA MAT November 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.1022 as compared to the previous close of Rs. 1000.6. The total number of shares traded during the day was 311608 in over 9852 trades.

The stock hit an intraday high of Rs. 1029.35 and intraday low of 993.6. The net turnover during the day was Rs. 315693116.

Source : Equity Bulls

Keywords